BioCentury
ARTICLE | Clinical News

BTA585: Phase IIa suspended enrollment

June 20, 2016 7:00 AM UTC

Aviragen voluntarily suspended enrollment in a double-blind, placebo-controlled, U.K. Phase IIa trial of oral BTA585 after 1 subject had “an increase of a cardiac enzyme level coupled with transient E...